Form 4 filed by LAV Biosciences Fund V, L.P.
LAV Biosciences Fund V, L.P. filed this Form 4 on ADARx Pharmaceuticals, Inc. with 12 transaction rows and 0 holding rows, accepted by EDGAR 2026-09-30 01:38:06 UTC.
- Accession
- 0001231919-26-001406
- Filer
- CIK 1764435
- Filed
- 2026-09-29
- Accepted by EDGAR
- Ingested
- Source
- EDGAR daily index
Issuer and reporting owners
Issuer: ADARx Pharmaceuticals, Inc. (CIK 1802369)
- LAV Biosciences Fund V, L.P. 10% owner
- LAV Fund VI Opportunities, L.P. 10% owner
- LAV Fund VI, L.P. 10% owner
Rows
| Security | Date | Code | Shares | Price | Owned after | Ownership |
|---|---|---|---|---|---|---|
| Common Stock | 2026-09-28 | C converted | +8,908,775 | 8,908,775 | D | |
| Common Stock | 2026-09-28 | C converted | +1,667,469 | 10,576,244 | D | |
| Common Stock | 2026-09-28 | C converted | +513,067 | 11,089,311 | D | |
| Common Stock | 2026-09-28 | C converted | +153,868 | 11,243,179 | D | |
| Common Stock | 2026-09-28 | C converted | +307,738 | 307,738 | I By LAV Fund VI, L.P. | |
| Common Stock | 2026-09-28 | C converted | +307,738 | 307,738 | I By LAV Fund VI Opportunities, L.P. | |
| Series A Preferred Stock derivative | 2026-09-28 | C converted | -10,438,412 | $0 | 0 | D |
| Series B Preferred Stock derivative | 2026-09-28 | C converted | -1,953,774 | $0 | 0 | D |
| Series B-1 Preferred Stock derivative | 2026-09-28 | C converted | -601,161 | $0 | 0 | D |
| Series C Preferred Stock derivative | 2026-09-28 | C converted | -180,288 | $0 | 0 | D |
| Series C Preferred Stock derivative | 2026-09-28 | C converted | -360,577 | $0 | 0 | I By LAV Fund VI, L.P. |
| Series C Preferred Stock derivative | 2026-09-28 | C converted | -360,577 | $0 | 0 | I By LAV Fund VI Opportunities, L.P. |